Results From Galdermas Phase IIIb Trials Demonstrate Rapid and LongLasting Effect of RelabotulinumtoxinA on Crows Feet and Frown Lines

Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines GL frown lines and lateral canthal lines LCL crows feet.

Related Keywords

Switzerland ,Jessica Cohen ,Christian Marcoux ,Emil Ivanov ,Las Vegas ,Corporate Communications ,Global Aesthetic Improvement Scale ,Subject Live Assessment ,Injectable Aesthetics ,Dermatological Skincare ,Vegas Cosmetic Surgery ,Aesthetic Dermatology ,Media Contact ,Communications Officer ,Communications Director ,Investor Relations ,Strategy Director ,Galderma Phase Iiib Trials Relabotulinumtoxina Glabellar Lines Lateral Canthal 43qm2106 Placebocontrolled Trial Global Aesthetic Improvement Scale Subject Live Assessment Results Injectable Aesthetics Pureplay Dermatology Dermatological Skincare Therapeutic Healthcare Professionals ,